Tissue Regenix Ltd, the regenerative medical device company, is pleased to announce that two patients have received the first OrthoPure™ XT decellularised tendons using Tissue Regenix patented dCELL® technology. This has been done as part of a clinical safety study by Tissue Regenix which is being conducted to secure a CE mark to enable launch of the OrthoPure™ XT in the EU in 2017.
Orthopaedic & Trauma Surgeon, Dr. Gabriel Oliver performed both surgical procedure at the Bellvitge University Hospital in Barcelona on Thursday 3rd December. Both patients had ruptured an ACL due to recreational sports; the first a 31 year old male playing football, the second a 32 year old female injured whilst skiing.
